Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 13/20 | 1.00 |
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16238581 | 0.90 | TDO2 (1.00) | TDO2IDO1PDE10AGSK3B | |
| SCHEMBL17531850 | 0.87 | TDO2 (0.79) | TDO2IDO1 | |
| SCHEMBL16247419 | 0.84 | TDO2 (1.00) | TDO2IDO1CYP3A4CYP2D6 | |
| SCHEMBL16238274 | 0.76 | TDO2 (0.80) | TDO2IDO1 | |
| SCHEMBL16247522 | 0.72 | TDO2 (1.00) | TDO2IDO1 | |
| SCHEMBL16238197 | 0.71 | TDO2 (0.54) | TDO2 | |
| SCHEMBL16247498 | 0.69 | TDO2 (0.55) | TDO2IDO1 | |
| SCHEMBL16247623 | 0.68 | TDO2 (0.82) | TDO2IDO1 | |
| SCHEMBL16238348 | 0.68 | TDO2 (0.71) | TDO2GSK3BCYP3A4CYP2D6 | |
| SCHEMBL16238345 | 0.68 | TDO2 (0.77) | TDO2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294212-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2019-05-21 | — | — | US | disclosed |
| EP-2970173-B1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD (IN) | 2018-05-09 | — | — | EP | disclosed |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PVT LTD | 2018-02-01 | — | — | US | disclosed |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PVT LTD | 2018-02-01 | — | — | US | disclosed |
| US-9815811-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2017-11-14 | — | — | US | disclosed |
| US-9815811-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2017-11-14 | — | — | US | disclosed |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2016-02-18 | — | — | US | disclosed |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2016-02-18 | — | — | US | disclosed |
| WO-2014186035-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294212-B2 | Inhibitors of the kynurenine pathway | IDO1, IDO2, KYNU | TDO2 6/4885IDO1 1/4885MAPK10 1853/4885 |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | IDO1, IDO2, KYNU | TDO2 6/4885IDO1 1/4885MAPK10 1853/4885 |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | IDO1, KYNU, IDO2 | TDO2 7/4885IDO1 1/4885MAPK10 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.